Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
about
Monoclonal antibody-based therapies for microbial diseasesProgress and problems in the application of focused ultrasound for blood-brain barrier disruption.Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiologyTreatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.Phage display in molecular imaging and diagnosis of cancer.Targeting of drugs and nanoparticles to tumors.HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection.Pretargeted radioimmunotherapy for hematologic and other malignanciesCancer radioimmunotherapy.Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer XenograftsTreatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice.Radiolabelled monoclonal antibodies in the treatment of metastatic cancerImaging virus-associated cancer.Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanomaReduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.Improvement of radioimmunotherapy using pretargeting.Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody constructA re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.Radionuclide carriers for targeting of cancer.A semiempirical model of tumor pretargeting.Safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinomaRadiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax.Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.Pretargeted molecular imaging and radioimmunotherapy.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsTargeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R).(99m)Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging.Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapyReply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies.
P2860
Q27490830-893D233B-6934-4384-9AEA-73E32C3F0099Q30487878-DE70A034-5ECA-4B8D-8BEA-5535100823FBQ33304454-DD9C5316-921C-4E2A-BC73-9447A429D528Q33395088-35EDA398-59C8-47B2-8161-421CC16D50D2Q33532734-2D8B99F3-F18D-4261-B2AE-25AD65F8C9CAQ33751710-7843B2B2-D00F-49CE-8C58-4A4EC9224CBDQ33862523-28F5C67D-0AC0-421A-9C95-10565161C1CDQ33996459-36A50F01-B458-4B7E-8F79-68494EFBF02CQ34113941-D07E9228-B26B-42BE-BC16-A00B3A820A73Q35070045-8EDB1798-1257-4F05-9557-473DDE875DAAQ35072954-2B8764CE-B8DF-4831-8333-557F4FB78D7BQ35643471-55230E3B-73D0-4215-B35C-1C5DB5B8EA9EQ35666553-18C770B5-17FA-417E-B43B-6861FBDC98D2Q35840380-96B2C861-2FB5-43EB-8180-98E296C78C48Q36015054-F3FD5E37-A2BF-4C14-9726-BBB6E5D5280CQ36021361-590CE8F1-0038-43D7-926C-9315F513F15BQ36082355-DC33A364-6FCF-4E53-B244-698B85124C13Q36567381-DC95B349-E469-4399-95CB-252B8989D197Q36883720-5CFEA78E-1518-4D9F-B44F-C53D1D8A723EQ36941931-6B364DE9-4641-4790-9DF2-96E45362E131Q36979699-CF37EAE3-3C3B-4A3E-9CE0-E3ED7DF117C5Q37146338-1D5417CF-AD1D-44C6-AEBA-8F7DDC5499D0Q37169112-BB8F5ADB-AB6A-41F6-A749-D6CF9B13CB81Q37174938-DD1D521D-BADD-45E5-A3C1-357C00998EF1Q37201878-52B8345C-3A31-44A9-B33F-4016DC8F86A7Q37237705-15328225-8929-4EDD-8AD0-CA9BCC217895Q37288717-B7A8CA42-625C-411D-80C7-D226FE869153Q37313173-FB3321B2-D1AF-4FAE-9B64-37D07086B948Q37409957-2786E96B-B72D-43C1-874A-8ED1ED65D13BQ37424092-18265E0E-A946-42F9-85C5-ACDBE2684F42Q37720857-BD461372-E39B-4EF5-AE96-9624D86CE496Q38022016-69B8E373-8A5D-4AAA-A1BF-8E7F9CBEBA3EQ38042256-194F9A24-23D0-49B6-BD3C-8BE42A845C1DQ38741116-8CA73E7D-FAF2-47FA-85D7-6D0AF11EA6FAQ38794260-4BA6678F-0FE8-4739-BF22-FC8F732E7C07Q39564060-BF6B25D2-E5B3-4CD6-BD18-A2A0769952C4Q41829288-C13C80D2-2ADB-4F5B-8F5A-50E801A3CCDBQ46088666-2A3F1B57-3E5E-482C-B2E1-C0FD55A75B94
P2860
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
@ast
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
@en
type
label
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
@ast
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
@en
prefLabel
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
@ast
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
@en
P1476
Perspectives on cancer therapy with radiolabeled monoclonal antibodies
@en
P2093
David M Goldenberg
Robert M Sharkey
P304
P407
P478
46 Suppl 1
P577
2005-01-01T00:00:00Z